Blog
RSS FeedPosted by Michael Wonder on 16 Jan 2023
AbbVie and Eli Lilly, two of the world’s largest pharmaceutical companies, have sent a warning signal to the UK government by leaving the voluntary medicines pricing agreement in protest over increasingly punitive revenue clawbacks
16 January 2023 - AbbVie and Lilly have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access, a ...
Posted by Michael Wonder on 16 Jan 2023
The game-changing plan to cut barriers to medical abortion
16 January 2023 - A push is under way to make medical abortion more accessible across Australia by cutting down ...
Posted by Michael Wonder on 15 Jan 2023
US to announce list of drugs for pricing negotiations 1 September
12 January 2023 - The US Government will announce a list of 10 prescription drugs for which it plans to ...
Posted by Michael Wonder on 13 Jan 2023
Recent patent reform bills and their implications for prescription drugs
13 January 2022 - In 2022, several bills were introduced in Congress to revamp US intellectual property law. ...
Posted by Michael Wonder on 13 Jan 2023
As CMS asks for the public’s feedback on implementing the Inflation Reduction Act, unresolved issues related to drug price negotiations remain
11 January 2022 - On 11 January, the Centers for Medicare and Medicaid Services (CMS) announced a timeline for implementation of ...
Posted by Michael Wonder on 12 Jan 2023
Intellia Therapeutics awarded Innovation Passport in the United Kingdom for NTLA-2002, an investigational genome editing treatment for hereditary angioedema
11 January 2023 - NTLA-2002 is a single dose genome editing therapeutic candidate designed to prevent angioedema attacks in people ...
Posted by Michael Wonder on 10 Jan 2023
US Supreme Court rebuffs Pfizer plan to help patients pay for heart medication
9 January 2023 - The US Supreme Court on Monday turned away Pfizer's bid to revive its plan to cover ...
Posted by Michael Wonder on 10 Jan 2023
Pharmacy benefit managers and the Federal Trade Commission: a relationship gone sour
9 January 2023 - On 7 June 2022, the Federal Trade Commission announced its decision to launch an inquiry into the ...
Posted by Michael Wonder on 10 Jan 2023
Four types of bias in medical AI are running under the FDA’s radar
9 January 2023 - Although artificial intelligence is entering health care with great promise, clinical artificial intelligence tools are prone ...
Posted by Michael Wonder on 04 Jan 2023
Options for CMS drug price negotiations
4 January 2023 - In 2026, the Inflation Reduction Act will allow the Centers for Medicare and Medicaid Services to negotiate ...
Posted by Michael Wonder on 02 Jan 2023
Korea to exclude Australia from new drug pricing reference country list
30 December 2022 - HIRA has decided to leave Australia as a reference country when it sets drug prices next ...
Posted by Michael Wonder on 30 Dec 2022
The FDA’s ‘breakthrough’ program for medical devices keeps gaining steam
28 December 2022 - For medical devices in the Breakthrough Devices Program, 2022 has been a breakout year. ...
Posted by Michael Wonder on 29 Dec 2022
Congressional report: US FDA broke own protocols in approving Biogen Alzheimer's drug
29 December 2022 - The US FDA failed to adhere to its own guidance and internal practices during the approval ...
Posted by Michael Wonder on 27 Dec 2022
New FDA guidance explains that Plan B is not an abortion pill
23 December 2022 - The FDA on Friday altered the language attached to emergency contraceptive pills to clarify that they ...
Posted by Michael Wonder on 23 Dec 2022
FDA’s new real world evidence program offers early agency feedback
21 December 2022 - The US FDA is aiming to improve the quality of real world evidence used in regulatory ...